About Pricing FAQs Blog

Loading clinical trials...

Your health journey, clearly organized.

Find Clinical Trials →

Legal

Privacy Policy
Terms of Service

© 2026 Clareo Health. All rights reserved.

Back to clinical trial search

COMPLETEDNCT04957641

A Study of the Burden of Illness and Treatment Patterns in Teenagers and Adults With Hereditary Angioedema

This study is about teenagers and adults with hereditary angioedema (HAE) type I and type II. In this study, the burden of illness means the impact of HAE in terms of long-term health outcomes and the...

Lead sponsor: Takeda•36 locations•View source on ClinicalTrials.gov

Clareo plain-language summary

What this study is about

Generating AI summary...

Save this trial guide to your notes

Keep your clinical trial research organized — questions to ask, what to expect, and key details.

Sponsors

Lead Sponsor

Takeda

Age

12 - No limit years

Sex

ALL

Healthy Volunteers

No

Inclusion Criteria

•Participant aged \>= 12 years at the time of the last documented HAE attack in the eligibility period.
•Physician-confirmed diagnosis (or confirmation in medical records) of HAE type I or type II.
•Participant had at least one documented HAE attack during the eligibility period.
•Participant is not adequately or sub-optimally controlled according to treating physician.
•Participant (or parent/legal guardian) is willing and able to comply with the study requirements and provides informed consent or assent.

Exclusion Criteria

•Participant enrolled in a therapeutic investigational drug or device trial during the observation period.
•Participant initiated long-term prophylaxis with Takhzyro® at any time since diagnosis.

Related studies

RECRUITINGPhase 3

Long-Term, Open-label Study of Oral Deucrictibant Extended-Release Tablet for Prophylaxis Against Angioedema Attacks in Adolescents and Adults With HAE

NCT06679881 · Hereditary Angioedema (HAE)

RECRUITINGPhase 3

STOP-HAE: A Phase 3 Study of ADX-324 in HAE

NCT06960213 · Hereditary Angioedema, HAE, and more

A Study Investigating the Effectiveness and Safety of Garadacimab for Treating Patients With Hereditary Angioedema (HAE)

NCT07001280 · Hereditary Angioedemas

RECRUITINGPhase 3

Donidalorsen Treatment in Children With Hereditary Angioedema

NCT07298447 · Hereditary Angioedema (HAE)

RECRUITINGPhase 3

A Study of Navenibart in Participants With Hereditary Angioedema

NCT06842823 · Hereditary Angioedema (HAE)

View all related studies →

Data from ClinicalTrials.govLast updated on ClinicalTrials.gov: June 26, 2023Terms

Trial snapshot

StatusCOMPLETED

Phase—

Enrollment221

Start dateApr 2022

Last updatedJun 26, 2023

Condition

Hereditary Angioedema

Locations shown

Medizinische Universitat Wien (Medical University of Vienna)

Vienna

UZ Antwerpen

Edegem

University Multiprofile Hospital for Active Treatment Aleksandrovska EAD

Sofia

For caregivers

Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.

Start free trial →

Data Source & Attribution

This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.

ClinicalTrials.gov last update: June 26, 2023Data synced to Clareo: June 28, 2026

Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.

Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.

View ClinicalTrials.gov Terms and Conditions